Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
Clinical trial NCT03221634 · WITHDRAWN
Trial details
- NCT number
- NCT03221634
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-01
- Primary completion
- 2019-03-20
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.